194 related articles for article (PubMed ID: 38227591)
41. The WAVE3/β-catenin oncogenic signaling regulates chemoresistance in triple negative breast cancer.
Wang W; Rana PS; Markovic V; Sossey-Alaoui K
Breast Cancer Res; 2023 Mar; 25(1):31. PubMed ID: 36949468
[TBL] [Abstract][Full Text] [Related]
42. Identification of a novel mechanism for reversal of doxorubicin-induced chemotherapy resistance by TXNIP in triple-negative breast cancer via promoting reactive oxygen-mediated DNA damage.
Chen Y; Feng X; Yuan Y; Jiang J; Zhang P; Zhang B
Cell Death Dis; 2022 Apr; 13(4):338. PubMed ID: 35414060
[TBL] [Abstract][Full Text] [Related]
43. Jagged2 promotes cancer stem cell properties of triple negative breast cancer cells and paclitaxel resistance via regulating microRNA-200.
Li CY; Miao KL; Chen Y; Liu LY; Zhao GB; Lin MH; Jiang C
Eur Rev Med Pharmacol Sci; 2018 Sep; 22(18):6008-6014. PubMed ID: 30280784
[TBL] [Abstract][Full Text] [Related]
44. A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.
Jovanović B; Mayer IA; Mayer EL; Abramson VG; Bardia A; Sanders ME; Kuba MG; Estrada MV; Beeler JS; Shaver TM; Johnson KC; Sanchez V; Rosenbluth JM; Dillon PM; Forero-Torres A; Chang JC; Meszoely IM; Grau AM; Lehmann BD; Shyr Y; Sheng Q; Chen SC; Arteaga CL; Pietenpol JA
Clin Cancer Res; 2017 Aug; 23(15):4035-4045. PubMed ID: 28270498
[No Abstract] [Full Text] [Related]
45. Epigenomic Profiling Advises Therapeutic Potential of Leukotriene Receptor Inhibitors for a Subset of Triple-Negative Breast Tumors.
Kalinkin AI; Sigin VO; Kuznetsova EB; Ignatova EO; Vinogradov II; Vinogradov MI; Vinogradov IY; Zaletaev DV; Nemtsova MV; Kutsev SI; Tanas AS; Strelnikov VV
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139172
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
[TBL] [Abstract][Full Text] [Related]
47. Role of inhibitor of yes-associated protein 1 in triple-negative breast cancer with taxol-based chemoresistance.
Li Y; Wang S; Wei X; Zhang S; Song Z; Chen X; Zhang J
Cancer Sci; 2019 Feb; 110(2):561-567. PubMed ID: 30467925
[TBL] [Abstract][Full Text] [Related]
48. Analysis of single-cell RNA-sequencing data identifies a hypoxic tumor subpopulation associated with poor prognosis in triple-negative breast cancer.
Shi Y; Huang X; Du Z; Tan J
Math Biosci Eng; 2022 Apr; 19(6):5793-5812. PubMed ID: 35603379
[TBL] [Abstract][Full Text] [Related]
49. Single-cell RNA-sequencing uncovers compound kushen injection synergistically improves the efficacy of chemotherapy by modulating the tumor environment of breast cancer.
Liu X; Bai M; Li H; Ye P; Duan X; Wu C; Huang Z; Lu S; Zhang J; Zhao Z; Guo F; You R; Qin W; Wang W; Han A; Shen L; Wang Y; Zhao Z; Luo H; Wu J
Front Immunol; 2022; 13():965342. PubMed ID: 36389835
[TBL] [Abstract][Full Text] [Related]
50. Knockdown of SERPINE1 reverses resistance of triple‑negative breast cancer to paclitaxel via suppression of VEGFA.
Zhang Q; Lei L; Jing D
Oncol Rep; 2020 Nov; 44(5):1875-1884. PubMed ID: 33000256
[TBL] [Abstract][Full Text] [Related]
51. Targeting the Id1-Kif11 Axis in Triple-Negative Breast Cancer Using Combination Therapy.
Thankamony AP; Murali R; Karthikeyan N; Varghese BA; Teo WS; McFarland A; Roden DL; Holliday H; Konrad CV; Cazet A; Dodson E; Yang J; Baker LA; George JT; Levine H; Jolly MK; Swarbrick A; Nair R
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32911668
[TBL] [Abstract][Full Text] [Related]
52. Hypoxia-induced tRNA-derived fragments, novel regulatory factor for doxorubicin resistance in triple-negative breast cancer.
Cui Y; Huang Y; Wu X; Zheng M; Xia Y; Fu Z; Ge H; Wang S; Xie H
J Cell Physiol; 2019 Jun; 234(6):8740-8751. PubMed ID: 30362543
[TBL] [Abstract][Full Text] [Related]
53. Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells.
Tian J; Raffa FA; Dai M; Moamer A; Khadang B; Hachim IY; Bakdounes K; Ali S; Jean-Claude B; Lebrun JJ
Br J Cancer; 2018 Dec; 119(12):1495-1507. PubMed ID: 30482914
[TBL] [Abstract][Full Text] [Related]
54. Ceritinib is a novel triple negative breast cancer therapeutic agent.
Dong S; Yousefi H; Savage IV; Okpechi SC; Wright MK; Matossian MD; Collins-Burow BM; Burow ME; Alahari SK
Mol Cancer; 2022 Jun; 21(1):138. PubMed ID: 35768871
[TBL] [Abstract][Full Text] [Related]
55. The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling.
von Wahlde MK; Hülsewig C; Ruckert C; Götte M; Kiesel L; Bernemann C
Gynecol Endocrinol; 2015 Feb; 31(2):160-4. PubMed ID: 25356777
[TBL] [Abstract][Full Text] [Related]
56. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial.
Filho OM; Stover DG; Asad S; Ansell PJ; Watson M; Loibl S; Geyer CE; Bae J; Collier K; Cherian M; O'Shaughnessy J; Untch M; Rugo HS; Huober JB; Golshan M; Sikov WM; von Minckwitz G; Rastogi P; Maag D; Wolmark N; Denkert C; Symmans WF
JAMA Oncol; 2021 Apr; 7(4):603-608. PubMed ID: 33599688
[TBL] [Abstract][Full Text] [Related]
57. RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC.
Kim SJ; Ju JS; Kang MH; Eun JW; Kim YH; Raninga PV; Khanna KK; Győrffy B; Pack CG; Han HD; Lee HJ; Gong G; Shin Y; Mills GB; Eyun SI; Park YY
Theranostics; 2020; 10(18):7974-7992. PubMed ID: 32724453
[TBL] [Abstract][Full Text] [Related]
58. MicroRNA-5195-3p enhances the chemosensitivity of triple-negative breast cancer to paclitaxel by downregulating EIF4A2.
Liu M; Gong C; Xu R; Chen Y; Wang X
Cell Mol Biol Lett; 2019; 24():47. PubMed ID: 31308851
[TBL] [Abstract][Full Text] [Related]
59. 10-Gingerol Enhances the Effect of Taxol in Triple-Negative Breast Cancer via Targeting ADRB2 Signaling.
Liang Y; Wu G; Luo T; Xie H; Zuo Q; Huang P; Li H; Chen L; Lu H; Chen Q
Drug Des Devel Ther; 2023; 17():129-142. PubMed ID: 36712945
[TBL] [Abstract][Full Text] [Related]
60. Adenomatous Polyposis Coli loss controls cell cycle regulators and response to paclitaxel in MDA-MB-157 metaplastic breast cancer cells.
Astarita EM; Maloney SM; Hoover CA; Berkeley BJ; VanKlompenberg MK; Nair TM; Prosperi JR
PLoS One; 2021; 16(8):e0255738. PubMed ID: 34370741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]